Europe: Academia and industry push for revisions to Clinical Trials Directive
27/9/2011
According to many UK/European academic and industry stakeholders, the EU's Clinical Trials Directive has "resulted in unnecessary complexity and bureaucracy that are hampering the progress of medical research by pushing up the time and costs needed to get clinical studies underway". More...
Author: Greer Deal, Director of Global Regulatory Services (GRS)